Avid Bioservices Inc (CDMO)

[2ndstr2thert]

This is for you ENTDOC .

The TNT platform is still alive. For those who do not know we have another platform technology that has been put on hold while are supposed partner reaps the benefits ?

http://online.liebertpub.com/doi/abs/10.1089/cbr.2012.1418?src=recsys&journalCode=cbr


Radiofrequency Ablation Before Intratumoral Injection of 131I-chTNT Improves the Tumor-to-Normal Tissue Ratio in Solid VX2 Tumor
To cite this article:
Shu-Guang Zheng, Hui-Xiong Xu, Ming-De Lu, Dian-Chao Yue, Xiao-Yan Xie, and Guang-Jian Liu. Cancer Biotherapy and Radiopharmaceuticals. November 2013, 28(10): 725-730. doi:10.1089/cbr.2012.1418.

Published in Volume: 28 Issue 10: November 14, 2013
Online Ahead of Print: August 21, 2013
Full Text HTML Full Text PDF (213 KB) Full Text PDF with Links (219.2 KB)
Author information
Shu-Guang Zheng,1,2 Hui-Xiong Xu,1,2 Ming-De Lu,1 Dian-Chao Yue,3 Xiao-Yan Xie,1 and Guang-Jian Liu1
1Department of Medical Ultrasonics, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
2Department of Medical Ultrasound, Tenth People's Hospital of Tongji University, Shanghai, China.
3Department of Nuclear Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Address correspondence to: Hui-Xiong Xu; Department of Medical Ultrasound, Tenth People's Hospital of Tongji University; No. 301 Yanchangzhong Road, Shanghai 200072, China
E-mail: [e-mail]
ABSTRACT
Purpose: This study was aimed to investigate whether the tumor necrosis induced by radiofrequency ablation (RFA) can improve the ratio of tumor-to-normal tissue (T/NT) after intratumoral injection of 131I-chTNT.

Materials and Method: Eighteen New Zealand rabbits bearing VX2 tumor on the thigh were randomly divided into two treatment groups (control group: intratumoral injection of 131I-chTNT alone; RFA group: RFA + intratumoral injection of 131I-chTNT 3 days after RFA) and each group was further divided into three subgroups I, II, and III (1–2?cm, 2–3?cm, and 3–4?cm in maximum diameter, respectively), by the tumor size. SPECT was performed to evaluate the T/NT on days 1, 8, and 15 after 131I-chTNT injection.

Results: After treatment, all rabbits underwent the SPECT whole-body scan and the T/NT was analyzed. The results showed that T/NT in the RFA group (55.45±41.83) was significantly higher compared with the control group (7.23±5.61) (F=18.89, p=0.001). Meanwhile, a linear ascending trend was found for T/NT in the RFA group along with the follow-up time (r=0.47, p=0.01). The tumor size or the dose of 131I-TNT injection had no significant effect on the variation of T/NT in both groups (p>0.05).

Conclusion: RFA before intratumoral injection of 131I-chTNT can dramatically improve T/NT, demonstrating the potential application of this combination therapy.

This paper was cited by:
Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models
Franziska Eckert, Julia Schmitt, Daniel Zips, Marcel A. Krueger, Bernd J. Pichler, Stephen D. Gillies, Wolfgang Strittmatter, Rupert Handgretinger, Karin Schilbach
Cancer Immunology, Immunotherapy. Aug 2016, Vol. 65, No. 8: 1003-1013
CrossRef
The Safety and Treatment Response of Combination Therapy of Radioimmunotherapy and Radiofrequency Ablation for Solid Tumor: A Study In Vivo
Shu-Guang Zheng, Hui-Xiong Xu, Le-Hang Guo, Lin-Na Liu, Feng Lu, David Loeb
PLoS ONE. May 2014, Vol. 9, No. 5: e96539
CrossRef
About This Journal... | Subscribe... | Buy Article...

Users who read this article also read
No Access
Sorafenib Blocks the HIF-1a/VEGFA Pathway, Inhibits Tumor Invasion, and Induces Apoptosis in Hepatoma Cells
Ming Xu, Yan-ling Zheng, Xiao-yan Xie, Jin-yu Liang, Fu-shun Pan, Shu-guang Zheng, Ming-de Lü
DNA and Cell Biology. Apr 2014: 275-281.
Abstract | Full Text PDF or HTML | Reprints | Permissions
No Access
The Usefulness of Combined Diagnostic CT and 99mTc-Octreotide Somatostatin Receptor SPECT/CT Imaging on Pulmonary Nodule Characterization in Patients
Liwei Wang, Xindao Yin, Feng Wang, Jianping Gu, Lingquan Lu, Qianzhi Wu, Baozhong Shen, Xiao-Feng Li
Cancer Biotherapy & Radiopharmaceuticals. Nov 2013: 731-736.
Abstract | Full Text PDF or HTML | Reprints | Permissions
No Access
Downregulated RhoBTB2 Expression Contributes to Poor Outcome in Osteosarcoma Patients
Zhe Jin, Ya-Xin Han, Xiao-Rui Han
Cancer Biotherapy & Radiopharmaceuticals. Nov 2013: 709-716.
Abstract | Full Text PDF or HTML | Reprints | Permissions
No Access
Preliminary Study of the Biodegradation and the Correlation Between In Vitro and In Vivo Release of 32P-Chromic Phosphate-Poly(L-lactide) Seeds
Jun Zhao, Guangtao Du, Yan Su, Guoqiang Shao, Zizheng Wang, Longbao Xu
Cancer Biotherapy & Radiopharmaceuticals. Nov 2013: 703-708.
Abstract | Full Text PDF or HTML | Reprints | Permissions
No Access
Aristolochia debilis Sieb. et Zucc. Induces Apoptosis and Reactive Oxygen Species in the HT-29 Human Colon Cancer Cell Line
Chunmei Li, Myeong-Hyeon Wang
Cancer Biotherapy & Radiopharmaceuticals. Nov 2013: 717-724.
Abstract | Full Text PDF or HTML | Reprints | Permissions
No Access
Radiolabeling, Stability Studies, and Pharmacokinetic Evaluation of Thulium-170-Labeled Acyclic and Cyclic Polyaminopolyphosphonic Acids
Kusum Vats, Tapas Das, Haladhar D. Sarma, Sharmila Banerjee, M.R.A. Pillai
Cancer Biotherapy & Radiopharmaceuticals. Nov 2013: 737-745.
Ab